日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial

卡瑞利珠单抗联合 CAPOX 方案(以卡瑞利珠单抗为基础的维持治疗)与单用 CAPOX 方案作为胃癌或胃食管交界处腺癌一线治疗的疗效比较:一项随机 3 期试验

Peng, Zhi; Zhang, Yanqiao; Xu, Huiting; Yang, Yan; Yang, Mudan; Zhang, Mingjun; Cheng, Ying; Chen, Xiaobing; Pan, Yueyin; Wang, Feng; Li, Qingshan; Xu, Nong; Liu, Likun; Gu, Kangsheng; Xiao, Juxiang; Zhang, Ruixing; Zhao, Qun; Chen, Jian; Lin, Lizhu; Chen, Yigui; Deng, Yanhong; Cai, Shirong; Bai, Bin; Wang, Yiru; Shen, Lin

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study

瑞维替尼治疗伴有中枢神经系统转移的EGFR突变型非小细胞肺癌患者:来自III期REZOR研究的中枢神经系统疗效

Yang, Sheng; Zhao, Yanqiu; Sun, Meili; Bi, Minghong; Zhu, Bo; Chen, Zhaohong; Yu, Huiqing; Zhang, Liangming; Wu, Lin; Zhou, Rui; Yao, Wenxiu; Li, Xingya; Han, Zhigang; Wang, Ke; Wang, Lijun; Wen, Meiling; Guo, Yanzhen; Lin, Yingcheng; Sun, Shenghua; Guo, Shuliang; Yi, Tienan; Zhao, Wenhua; Yu, Zhuang; Qin, Jianwen; Pan, Yueyin; He, Zhiyong; Ye, Feng; Shi, Huaqiu; Fang, Jian; Ma, Rui; Lu, Hong; Zhang, Hua; Shi, Jianhua; Gao, Jinghua; Cui, Jiuwei; Li, Manxiang; Yi, Shanyong; Cang, Shundong; Shu, Yongqian; Zhang, Don; Peng, Jirong; Gao, Feng; Wang, Tingting; Zhou, Anqi; Shi, Yuankai

Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA

通过循环游离染色体外环状DNA片段大小选择检测原发性癌症类型

Fang, Jingwen; Luo, Songwen; Li, Shouzhen; Xu, Yehong; Wang, Jing; Shan, Benjie; Hu, Mingjun; Yu, Qiaoni; Zhang, Wen; Liu, Ke; Shao, Yunying; Yang, Jiaxuan; Zhou, YouYang; Xu, Guangtao; Yao, Xinfeng; Sun, Ruoming; Zhang, Mengyuan; Li, Kun; Xu, Xihai; Zhang, Yongliang; Zhang, Zhihong; Han, Xinghua; Pan, Yueyin; Guo, Chuang; Qu, Kun

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study

IBI389(一种抗Claudin18.2×CD3双特异性抗体)在实体瘤和胃或胃食管肿瘤患者中的安全性和初步疗效结果:一项1期剂量递增和扩展研究

Li, Xiaoyu; Dai, Ruihong; Xu, Qi; Guo, Zengqing; Hu, Changlu; Sun, Yuping; Niu, Zuoxing; Hao, Jihui; Zhang, Mingjun; Dai, Guanghai; Hua, Dong; Pan, Yueyin; Wang, Xin; Wei, Shuqing; Chen, Xiaobing; Wu, Qian; Zhang, Yulong; Zhou, Hui; Ying, Jieer; Zheng, Li; Bi, Feng

Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)

中国乳腺癌内分泌治疗专家共识(2026版)

Yuan, Yang; Yin, Yongmei; Wang, Shu; Liu, Yueping; Yang, Jin; Yan, Min; Mo, Xueli; Pan, Yueyin; Wang, Xiaojia; Wang, Haibo; Li, Jianbin; Wang, Shusen; Wu, Jiong; Song, Erwei; Jiang, Zefei

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

HA121-28 在晚期实体瘤和 RET 融合阳性非小细胞肺癌患者中的安全性、药代动力学和疗效:一项多中心、开放标签、单臂 1/2 期试验

Ruan, Dan-Yun; Huang, Wen-Wen; Li, Yongsheng; Zhao, Yanqiu; Shi, Yehui; Jia, Yuming; Cang, Shundong; Zhang, Wei; Shi, Jianhua; Chen, Jun; Lin, Jie; Liu, Yunpeng; Xu, Jianming; Ouyang, Weiwei; Fang, Jian; Zhuang, Wu; Liu, Caigang; Bu, Qing; Li, Manxiang; Meng, Xiangjiao; Sun, Meili; Yang, Nong; Dong, Xiaorong; Pan, Yueyin; Li, Xingya; Qu, Xiujuan; Zhang, Tongmei; Yuan, Xianglin; Hu, Sheng; Guo, Wei; Li, Yalun; Li, Shengqing; Liu, Dongying; Song, Feixue; Tan, Liping; Yu, Yan; Yu, Xinmin; Zang, Aimin; Sun, Chang; Zhang, Qian; Zou, Kai; Dan, Mo; Xu, Rui-Hua; Zhao, Hongyun

Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS(G12C) inhibitor-naïve Chinese patients with KRAS(G12C)-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

IBI351(富泽拉西布)单药治疗KRAS(G12C)突变型转移性结直肠癌且既往未接受过KRAS(G12C)抑制剂治疗的中国患者的疗效和安全性:两项研究I期部分的汇总分析

Yuan, Ying; Deng, Yanhong; Jin, Yongdong; Guo, Zengqing; Pan, Yueyin; Wang, Cunji; Wang, Zhiwu; Hu, Yi; Hua, Dong; Meng, Xiangjiao; Zhang, Zhiye; Zhao, Mingfang; Dong, Xiaorong; Huang, Dingzhi; Li, Xiaoyan; Liu, Lian; Sun, Meili; Wang, Huijuan; Wang, Xiuwen; Yang, Nong; Zhang, Mingjun; Hu, Sheng; Wu, Dongde; Huang, Jingjing; Zhang, Sujie; Huang, Mengna; Ding, Kefeng

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

CLDN18.2靶向抗体药物偶联物IBI343治疗晚期胃癌或胃食管交界处腺癌:一项I期试验

Liu, Jia; Yang, Jianwei; Sun, Yuping; Gong, Jifang; Yue, Jinbo; Pan, Yueyin; Sun, Meili; Song, Rongfeng; Xiao, Xiuying; Tazbirkova, Andrea; Ruan, Jian; Liu, Zhenyang; Liu, Zimin; Li, Zhihua; Sheng, Lili; Qin, Yanru; Ying, Jieer; Yu, Xianjun; Zhang, Jian; Mou, Yiping; Lu, Chuangxin; Chen, Ping; Li, Suyi; Li, Jie; Qu, Xiujuan; Deng, Ting; Du, Juan; Zhou, Aiping; Li, Enxiao; Yuan, Xianglin; Liang, Xinjun; Yu, Weiming; Morris, Michelle; Luo, Yang; Zhao, Xin; Guo, Yingmei; Zhou, Hui; Shen, Lin

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

乐伐替尼联合帕博利珠单抗和化疗对比单纯化疗治疗晚期转移性胃食管腺癌:III期随机LEAP-015研究

Shitara, Kohei; Lorenzen, Sylvie; Li, Jin; Bai, Yuxian; Fernández, Manuel González; Aguilar, Mynor; Shoji, Hirokazu; Reyes-Cosmelli, Felipe; Peña, Yovany Rodriguez; Corrales, Luis; Wyrwicz, Lucjan; Eyzaguirre, Daniel Acosta; Pan, Yueyin; Ryu, Min-Hee; Cohen, Deirdre J; Wainberg, Zev A; Ku, Geoffrey; Tabernero, Josep; Van Cutsem, Eric; Qin, Shu-Kui; Oh, Do-Youn; Xu, Jianming; Liang, Li Wen; Bordia, Sonal; Bhagia, Pooja; Rha, Sun Young

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment

脂质代谢重编程:乳腺癌进展和肿瘤微环境中的无名英雄

Wan, Mengting; Pan, Shuaikang; Shan, Benjie; Diao, Haizhou; Jin, Hongwei; Wang, Ziqi; Wang, Wei; Han, Shuya; Liu, Wan; He, Jiaying; Zheng, Zihan; Pan, Yueyin; Han, Xinghua; Zhang, Jinguo